$ZEPP

Zepp Health Corporation to Report First Quarter 2026 Financial Results on June 8, 2026

Zepp Health Corporation (NYSE: ZEPP) said it will release its unaudited first-quarter 2026 financial results on June 8, 2026. The company will host a conference call at 9:30 p.m. ET the same day, with a live webcast and an archived version on its investor site. A telephone replay will be available until June 15, 2026.

Original reporting
Published May 26, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 12:50 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ZEPP
Neutral
medium confidence
Mentioned
$ZEPP
Relevance
7/10
alphai data visualization · based on prnewswire.com
Decision brief

The 30-second read

$ZEPPNeutralMed
01

Why it matters

The main tradable element is the upcoming earnings catalyst; without new numbers, the market reaction will likely hinge on reported performance versus expectations and any guidance commentary.

02

Market read

This sets the next earnings-driven volatility window for ZEPP, but provides no new operational or financial information yet.

03

What to watch

Watch for any pre-announcement leaks, changes in analyst estimates ahead of June 8, and whether the company’s prior quarter trends suggest upside/downside risk.

Relevance 7/10Timing: High—earnings call on June 8, 2026 (9:30 p.m. ET) is the next defined event.

Background

Zepp Health announced it will report unaudited first-quarter 2026 financial results and host an earnings call on June 8, 2026.

Company-level read

Ticker impact

$ZEPPNeutralMedium confidence
Context

Zepp Health scheduled its Q1 2026 results for June 8, 2026, setting a near-term catalyst for earnings expectations and guidance read-through.

Expected impact

Moderate pre-earnings volatility; direction will depend on Q1 revenue/margins and any forward guidance released on June 8.

Evidence & confidence

The article contains no financial figures or guidance, but it clearly establishes the earnings call date/time, which typically affects short-term trading and implied volatility.

Market effects

Smart-wearables/health-tech names may see mild sentiment spillover as traders reprice the group’s near-term earnings calendar.

Limited—event is company-specific, though Zepp’s global footprint could influence broader investor attention to consumer health wearables.

Low—no international deal/regulatory development; impact is primarily on ZEPP positioning.

Counterpoint

Because the release is only a scheduling notice, the stock may trade mostly on broader market/sector moves until actual results are published.

Key entities

  • Zepp Health Corporation

    Smart wearables and health technology provider scheduling Q1 2026 earnings release and conference call.

  • June 8, 2026 earnings call

    9:30 p.m. ET conference call time for Q1 2026 results; replay available until June 15, 2026.

Related articles

$ZEPPMed

Zepp Health Corp (ZEPP) (Q2 2026) Earnings Call Highlights: Returns to Growth

Zepp Health Corp (ZEPP) reported Q2 2026 earnings with revenue challenges due to supply constraints and macroeconomic pressures. Q3 revenue guidance is $68-$73M, a 4%-10% YoY decline. Adjusted operating loss widened to $11.1M. The company faces higher component costs and production delays for new products, but expects growth in Q4. Cash position is $106.3M, with debt levels managed.

$ZEPPMed

Zepp Health Corp (ZEPP): Financial results for Q2 2026

Zepp Health Corp (ZEPP) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results MILPITAS, Calif., September 1, 2026 /PRNewswire/ -- Zepp Health Corporation (NYSE: ZEPP) (“Zepp”, the “Company” or “we”) today announced its unaudited financial results for the second

$SEDGHighAI 8/10

Trump Just Gave SolarEdge Stock a Lift. How You Should Play SEDG Here.

SolarEdge reported Q2 2026 non-GAAP revenue of $345.5M, up 23% YOY, and returned to profitability with a $10.2M operating profit. EPS beat estimates at $0.05. Analysts expect improved losses for FY 2026 and 2027. UBS upgraded SEDG to 'Buy' with a $42 target, citing potential market share gains, while others remain cautious.

$MDTHighAI 8/10

Medtronic’s Stars Are Aligning for a Price Recovery

Medtronic (MDT) reported Q1 FY2027 with adjusted operating earnings up 14.9%, adjusted EPS up 15.1%, and free cash flow more than doubling. The company raised revenue and EPS guidance, exceeding consensus. Analysts responded positively, with a consensus Moderate Buy rating and price targets suggesting 10-30% upside. MDT's stock rose 5% premarket. Risks include cybersecurity concerns from a recent breach.

$ARRYMedAI 8/10

Spotting Winners: Array (NASDAQ:ARRY) And Renewable Energy Stocks In Q2

Array (ARRY) fell 22.5% post-earnings, trading at $4.37. Bloom Energy (BE) surged 27.1% after reporting $1.07B revenue, up 166% YoY, beating estimates. Fluence Energy (FLNC) dropped 26.6% with $649.8M revenue, missing expectations. EnerSys (ENS) declined 3.3% despite beating EPS estimates. First Solar (FSLR) fell 3.1% after mixed results.